<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896284</url>
  </required_header>
  <id_info>
    <org_study_id>BMF-AFLI-2013-01</org_study_id>
    <secondary_id>2013-000848-26</secondary_id>
    <nct_id>NCT01896284</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor</brief_title>
  <acronym>MACBETH</acronym>
  <official_title>Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barcelona Macula Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barcelona Macula Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with neovascular age-related macular degeneration who do not respond to usual&#xD;
      treatment with conventional medications may respond to a new drug of the same class which is&#xD;
      designed to block a larger fraction of proangiogenic factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with no fluid on Optical Coherence Tomography (OCT) after loading dose of aflibercept</measure>
    <time_frame>Week 12</time_frame>
    <description>At week 12 an OCT will be performed to evaluate the changes in intra or subretinal fluid and to determine the percentage of patients with no fluid after 3 doses of aflibercept injected on baseline visit, week 4 and week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in best corrected visual acuity (BCVA)after loading dose</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT central foveal thickness after loading dose</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic and Visual Acuity outcomes maintained during (every 8 weeks) treatment.</measure>
    <time_frame>week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the time to resolution of any intra/sub retinal fluid on OCT</measure>
    <time_frame>week 4,8,12,24,32,40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe safety of this cohort of patients</measure>
    <time_frame>baseline, week 4, 8, 12, 24, 32 and 40</time_frame>
    <description>Describe the safety of aflibercept in study patients by determining ocular and non ocular adverse events classified according to type, frequency and severity during 40 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>0.5mg AFLIBERCEPT injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5mg aflibercept</intervention_name>
    <description>0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.</description>
    <arm_group_label>0.5mg AFLIBERCEPT injection</arm_group_label>
    <other_name>EYLEA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Men and women ≥ 50 years of age.&#xD;
&#xD;
          -  Any choroidal neovascular membranes (CNVM) lesion (occult, minimally classic or&#xD;
             classic) secondary to age-related macular degeneration&#xD;
&#xD;
          -  Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of:&#xD;
             20/32 to 20/320 (letter score of 73 to 25) in the study eye.&#xD;
&#xD;
          -  Able to return for ALL clinic visits and complete all study-related procedures.&#xD;
&#xD;
          -  Absence of other ocular diseases that could affect visual acuity.&#xD;
&#xD;
          -  Patients without optimal response to ranibizumab or bevacizumab defined as:&#xD;
&#xD;
               -  Patient with significant persistent or recurrent fluid (intraretinal or&#xD;
                  subretinal) on OCT or any leakage on fluorescein angiography despite at least 4&#xD;
                  injections within last 6 months, being the last OCT with presence of fluid within&#xD;
                  the 6 weeks after last treatment with ranibizumab or bevacizumab.&#xD;
&#xD;
               -  Patient with significant persistent or recurrent fluid (intraretinal or&#xD;
                  subretinal) on OCT or any leakage on fluorescein angiography despite three&#xD;
                  monthly treatment with ranibizumab or bevacizumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No scar, fibrosis, or atrophy involving the center of the fovea&#xD;
&#xD;
          -  No retina pigment epithelium (RPE) rip/tear involving the central fovea&#xD;
&#xD;
          -  Participation in another simultaneous interventional clinical trial&#xD;
&#xD;
          -  Prior treatment with anti-VEGF or steroids therapy in the study eye within 28 days of&#xD;
             baseline&#xD;
&#xD;
          -  Prior treatment with photodynamic therapy (PDT)&#xD;
&#xD;
          -  Intraocular surgery (including cataract surgery) in the study eye within 2 months&#xD;
             preceding Baseline&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for&#xD;
             AMD in the study eye&#xD;
&#xD;
          -  Active intraocular inflammation in the study eye&#xD;
&#xD;
          -  History of cerebral vascular accident, myocardial infarction, transient ischemic&#xD;
             attacks within 3 months of study enrollment.&#xD;
&#xD;
          -  Unable to undergo fluorescein angiography or fundus photography because of&#xD;
             uncontrolled allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Mones, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Macula Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Juan Donate, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Suárez de Figueroa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosipital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Luis Olea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Son Espases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Cabrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Insular de Canarias</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Sarasols, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari General de Catalunya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Araiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Clínico Quirúrgico de Oftalmología de Bilbao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Maria Ruiz-Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Albacete</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ignasi Jürgens, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catala de Retina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barcelona Macula Foundation</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 22, 2021</submitted>
    <returned>May 13, 2021</returned>
    <submitted>May 14, 2021</submitted>
    <returned>June 8, 2021</returned>
    <submitted>June 9, 2021</submitted>
    <returned>June 29, 2021</returned>
    <submitted>June 30, 2021</submitted>
    <returned>July 20, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

